Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced its participation in CANCERPREV, a
research and training program composed of top-tier research and
teaching institutions and life science/pharma companies. CANCERPREV
is principally focused on advancing the understanding of how breast
and skin cancer can be prevented.
Life science researchers participating in CANCERPREV programs
receive cross-disciplinary training from cancer biologists,
epidemiologists, mathematicians and geneticists to better
understand the key factors in cancer development, including
hormonal stimulation, chronic inflammation and lifestyle risks. A
central focus of the consortium’s research is on examining sex
hormone signaling and chronic inflammation in breast tissue and
skin as benchmarks of early cancer development in organs with
reproductive and non-reproductive functions, respectively.
The European Commission recently granted CANCERPREV funding
under its Horizon 2020 research and innovation program.
As a member of the consortium, Fluidigm is providing researchers
with training and support to maximize the knowledge-generating
power of the company’s cutting-edge mass cytometry and
microfluidics technologies. These technologies include the Helios™
system and Hyperion™ Imaging System, which employ mass cytometry,
and the Juno™ and Biomark™ microfluidics systems, all of which are
used throughout the academic and private sector research and drug
development communities to advance the discovery and deployment of
cancer biomarkers.
“Fluidigm is pleased for the opportunity to participate in
CANCERPREV, and we are excited to support the consortium’s efforts
to communicate meaningful oncology and immuno-oncology insights
more broadly throughout the life science research community,” said
Roberto Spada, PhD, who leads business development for
Fluidigm in Europe and the Middle East. “Ultimately, our goal is to
contribute to the acceleration of timelines for drug development
and implementation of new therapies for cancer prevention.”
“Cancer knows no boundaries, and with rates continuing to
increase globally, now more than ever we need to better understand
the key factors in cancer development in order to properly prevent
this disease,” said Gian Paolo Dotto, MD, PhD, University of
Lausanne, one of the principal investigators of the consortium.
“We’re grateful for the training, support and technology Fluidigm
is providing across a wide range of instruments and systems, and
look forward to continuing to work together towards our mission of
building a global foundation of cancer knowledge.”
In addition to Fluidigm, partners in the CANCERPREV consortium
include the International Cancer Prevention Institute, Helsana
Insurance Group, The Middle East Children’s Institute
International, Haute Ecole Spécialisée de Suisse Occidentale
(HES-SO) – La Source, University of Southern Denmark, AstraZeneca
UK Limited and Swiss Vitamin Institute.
“Fluidigm’s industry-leading mass cytometry and microfluidics
technologies are helping to advance research for diagnosis and
treatment of patients with cancer, but we recognize that prevention
is the most powerful tool we have against a disease that is the
second leading cause of death on a global basis,” said Chris
Linthwaite, President and CEO of Fluidigm. “We are proud to partner
with CANCERPREV to support the next generation of researchers, and
our team is eager to support discovery of prevention insights that
may inform new therapies and save lives.”
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, and plant and animal research
laboratories worldwide. Together with them, we strive to increase
the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, Biomark, CyTOF, Helios,
Hyperion, and Juno are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are the
sole property of their respective owners. Fluidigm products
are for Research Use Only. Not for use in diagnostic
procedures.
Forward-Looking Statements for FluidigmThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding potential
advancements in research through Fluidigm’s mass cytometry and
microfluidics technologies and expectations for participation in a
research consortium. Forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including but
not limited to potential product performance and quality issues;
intellectual property risks; and competition. Information on these
and additional risks and uncertainties and other information
affecting Fluidigm business and operating results is contained in
Fluidigm’s Annual Report on Form 10-K for the year ended December
31, 2019, and in its other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and webcasts.
About CANCERPREVAt CANCERPREV we work
tirelessly to understand how breast and skin cancer can
be prevented. Our team consists of cancer biologists,
epidemiologists, nutrition experts, health care professionals
experienced in cancer development and
treatment, mathematicians, and representatives of vulnerable
socio-economic groups, as well as young researchers training
for leadership roles in the public and private sector. It can
take decades to transform research results into effective public
health measures that could benefit all of us. This is why we commit
to openly share the data and the results of our work, both with
other scientists and with the public. For more information, visit
cancerprev.com
Fluidigm
Media: Mark Spearman Senior Director, Corporate
Communications 650 243 6621mark.spearman@fluidigm.com
Investors: Agnes Lee Vice President, Investor
Relations 650 416 7423 agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2024 to May 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From May 2023 to May 2024